<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28538759</article-id><article-id pub-id-type="pmc">5421468</article-id><article-id pub-id-type="doi">10.5935/abc.20170044</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Cardiac Surgery - Adults</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparison of Two Central Venous Pressure Control Strategies to
Prevent Atrial Fibrillation After Coronary Artery Bypass
Grafting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>da Costa</surname><given-names>Mario Augusto Cray</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Lirani</surname><given-names>Wesley</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Wippich</surname><given-names>Ana Caroline</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Luana</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Tolentino</surname><given-names>Eduardo de Souza</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Zampar</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Schafranski</surname><given-names>Marcelo Derbli</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1"> Universidade Estadual de Ponta Grossa, Ponta Grossa, PR - Brazil
</aff></contrib-group><author-notes><corresp id="c1"><bold>Mailing Address: Mario Augusto Cray da Costa</bold>, Rua
Coronel Bittencourt, 567. Postal Code 84010-290, Centro, Ponta Grossa, PR -
Brazil. E-mail: <email>drmarioaugusto@uol.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>4</month><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>108</volume><issue>4</issue><fpage>297</fpage><lpage>303</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Atrial fibrillation (AF) takes place in 10-40% of patients undergoing
coronary artery bypass grafting (CABG), and increases cardiovascular
mortality. Enlargement of atrial chambers is associated with increased AF
incidence, so patients with higher central venous pressure (CVP) are
expected to have larger atrial distension, which increases AF incidence.</p></sec><sec><title>Objective</title><p>To compare post-CABG AF incidence, following two CVP control strategies.</p></sec><sec><title>Methods</title><p>Interventional, randomized, controlled clinical study. The sample comprised
140 patients undergoing CABG between 2011 and 2015. They were randomized
into two groups, G15 and G20, with CVP maintained &#x02264; 15
cmH<sub>2</sub>O and &#x02264; 20 cmH<sub>2</sub>O, respectively.</p></sec><sec><title>Results</title><p>70 patients were included in each group. The AF incidence in G15 was 8.57%,
and in G20, 22.86%, with absolute risk reduction of 14.28%, and number
needed to treat (NNT) of 7 (p = 0.03). Mortality (G15 = 5.71%; G20 = 11.42%;
p = 0.07), hospital length of stay (G15 = 7.14 days; G20 = 8.21 days; p =
0.36), number of grafts (median: G15 = 3, G2 = 2; p = 0.22) and
cardiopulmonary bypass use (G15 = 67.10%; G20 = 55.70%; p = 0.22) were
statistically similar. Age (p = 0.04) and hospital length of stay (p =
0.001) were significantly higher in patients who developed AF in both
groups.</p></sec><sec><title>Conclusion</title><p>Keeping CVP low in the first 72 post-CABG hours reduces the relative risk of
AF, and may be useful to prevent AF after CABG. </p></sec></abstract><kwd-group><kwd>Central Venous Pressure</kwd><kwd>Atrial Fibrillation/prevention</kwd><kwd>Myocardial Revascularization</kwd><kwd>Postoperative Care</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Atrial fibrillation (AF) is an arrhythmia that results from abnormal depolarization,
causing loss of the atrial contraction ability. It is related to increased risk for
stroke and mortality.<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref></sup></p><p>Atrial fibrillation in the postoperative period (PO) of coronary artery bypass
grafting (CABG) occurs in 5-40% of patients, usually from the second to the fourth
PO day, peaking on the second day.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> Its pathophysiology is
multifactorial and includes oxidative stress, systemic inflammatory response,
excessive production of catecholamines, changes in autonomic tone and connexin
expression. Such factors cause dispersion of atrial refractoriness, alter atrial
electrical conduction and predispose to arrhythmia.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup></p><p>The following risk factors are related to the higher incidence of post-CABG AF:
advanced age, peripheral vascular disease, chronic obstructive pulmonary disease
(COPD), diabetes mellitus, systemic arterial hypertension, valvular heart disease,
left atrial enlargement, left ventricular dysfunction, history of previous AF or
acute myocardial infarction (AMI), suspension of beta-blockers in the preoperative
period, use of cardiopulmonary bypass (CPB), and increased PO sympathetic
tone.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup></p><p>Atrial fibrillation in the PO period of CABG worsens the patient's hemodynamic
status, because of the increased risk for congestive heart failure and embolic
events in the long run. Stroke is a major complication, observed in 2% of surgical
patients. In addition, AF has been associated with higher in-hospital mortality and
worse survival in the long run.<sup><xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r7" ref-type="bibr">7</xref></sup> Such complications justify the need
for prophylactic measures for post-CABG AF.</p><p>The rationale of this study is based on the following hypothesis: the increased
volume of the atria is associated with increased AF incidence;<sup><xref rid="r8" ref-type="bibr">8</xref></sup> therefore, patients with higher
central venous pressure (CVP) are expected to have greater atrial distension, and,
thus, a higher AF incidence, in addition to being predisposed to pulmonary
congestion, hypoxemia and atrial wall edema, factors that contribute to increase the
incidence of that arrhythmia. Thus, CVP control could be useful to prevent post-CABG
AF. Aiming at testing that hypothesis, the post-CABG AF incidence was assessed under
two CVP control strategies.</p></sec><sec><title>Objective</title><p>This study aimed at assessing whether the incidence of AF 48 to 72 hours after CABG
differs between two CVP control strategies (based on intent to treat), by comparing
two groups: G15 (CVP &#x02264; 15 cmH<sub>2</sub>O) and G20 (CVP &#x02264; 20
cmH<sub>2</sub>O), AF being the primary outcome. The secondary outcome was to
compare hospital length of stay after CABG, as well as mortality, between both
groups.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Type of study</title><p>This is a clinical, randomized, controlled, interventional and prospective study
performed at the Intensive Care Unit (ICU) of Santa Casa de Miseric&#x000f3;rdia
of Ponta Grossa, Paran&#x000e1; State, in partnership with the State University
of Ponta Grossa (UEPG). The analysis was performed with data prospectively
collected. This study project was approved by the Ethics Committee in Research
UEPG, abides by the 1975 Declaration of Helsinki, and all participants provided
written informed consent before surgery.</p></sec><sec><title>Inclusion and exclusion criteria</title><p>This study sample comprised patients undergoing CABG at the Cardiac Surgery
Service of the Santa Casa de Miseric&#x000f3;rdia of Ponta Grossa from January
2011 to December 2015.</p><p>Patients with the following characteristics were excluded: undergoing CABG in
association with another procedure; history of preoperative AF; contraindication
to maintain CVP below the established values (such as severe pulmonary
hypertension); severe chronic renal failure, determined by a glomerular
filtration rate &#x0003c; 30 mL/min; severe left ventricular dysfunction; use of high
doses of vasoactive drugs, such as dopamine or dobutamine &#x0003e; 7mcg/kg/min or
noradrenaline &#x0003e; 0.7mcg/kg/min; no use of beta-blocker or statin in the
preoperative period, or no diet reintroduction, and after vasoactive drug
suspension in the PO period; need for more than 20 ampoules of furosemide within
24 hours to maintain CVP levels.</p></sec><sec><title>Outcomes</title><p><bold>Primary outcome:</bold> presence of AF 48 to 72 hours after CABG, on
continuous electrocardiographic monitoring (cardioscope) and documented on
12-lead electrocardiogram (ECG).</p><p><bold>Secondary outcomes:</bold> in-hospital mortality and hospital length of
stay after CABG.</p></sec><sec><title>Definition of the groups and data collection</title><p>Patients were randomized into two groups by use of draw: G15, with a CVP goal of
&#x02264; 15 cmH<sub>2</sub>O; and G20, with a CVP goal of &#x02264; 20
cmH<sub>2</sub>O. The strategy of CVP control consisted of measuring CVP
every 2 hours for 72 hours after CABG, or until discharge from the ICU. The
minimum ICU length of stay was 48 hours. Whenever CVP reached its cutoff point,
a furosemide ampoule was intravenously administered, from the sixth hour on,
because, in the first 6 post-CABG hours, hemodynamic instability is higher.
Vasoactive or anti-hypertensive drugs were administered to maintain a mean
arterial pressure (MAP) of 60-100 mm Hg. The AF incidence was compared between
the groups, detected by use of continuous electrocardiographic monitoring
(cardioscope) and confirmed on 12-lead ECG.</p><p>The following data were collected daily: CVP levels, need for furosemide, AF
occurrence within the post-CABG period (48 to 72 hours), hospital length of stay
and in-hospital death.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> The
following surgical data and comorbidities were collected from the patients'
standard preoperative and PO forms: age, sex, previous AF, diabetes mellitus,
COPD, chronic kidney disease, peripheral vascular disease, left ventricular
function, recent AMI, use of CPB, and number of grafts.</p></sec><sec><title>Statistical analysis</title><p>The statistical analysis was performed in two steps. In the first, the following
variables were compared between the G15 and G20 groups: age, sex, diabetes
mellitus, COPD, peripheral arterial disease, recent AMI within three months from
surgery, moderate left ventricular dysfunction (ejection fraction &#x0003c; 50% and
&#x0003e; 35%), glomerular filtration rate, AF incidence, in-hospital death,
post-CABG hospital length of stay (days), number of grafts, and use of CPB. The
quantitative variables were expressed as medians for nonparametric data, or as
means for parametric data, and coefficient of variation (CV). The qualitative
variables were expressed as absolute numbers and percentages. In the second
step, the patients were divided into two groups, one group of those who
developed AF and the other group of those who did not developed AF, and the
following variables were compared between the new groups: age, in-hospital
death, post-CABG hospital length of stay (days), number of grafts, and use of
CPB. Their statistical analysis was performed with the MedCalc software. The
qualitative variables were assessed by using two-tailed Fisher exact test. The
quantitative variables had their normality tested by use of Shapiro-Wilk test;
because the data had nonparametric distribution, they were assessed by use of
two-tailed Mann-Whitney test. To assess the effect size, absolute risk reduction
(ARR) and relative risk reduction (RRR) were used, and, for qualitative
variables, the number needed to treat (NNT). The statistical significance level
adopted was p &#x0003c; 0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The sample comprised 140 patients randomized into two groups, with 70 patients each:
G15, CVP maintained &#x02264; 15 cmH<sub>2</sub>O; and G20, CVP maintained &#x02264;
20 cmH<sub>2</sub>O. The comparative analysis of patients' age and sex is shown in
<xref ref-type="table" rid="t1">Table 1</xref>. The mean ages of the groups were
60 years (CV = 0.17) in G15, and 63 years (CV = 0.15) in G20 (p = 0.6). The male sex
predominated in both groups (G15=67.10%; and G20 = 81.43%; p = 0.07).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients' age and sex according to group (G15: CVP control &#x02264; 15
cmH<sub>2</sub>O; and G20: CVP control &#x02264; 20 cmH<sub>2</sub>O)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">G15 (n = 70)</th><th align="center" rowspan="1" colspan="1">G20 (n = 70)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (CV)</td><td align="center" rowspan="1" colspan="1">60 (0.17)</td><td align="center" rowspan="1" colspan="1">63 (0.15)</td><td align="center" rowspan="1" colspan="1">0.6 <sup><xref ref-type="table-fn" rid="TFN2">&#x02020;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, n (%)</td><td align="center" rowspan="1" colspan="1">47 (67.1)</td><td align="center" rowspan="1" colspan="1">57 (81.43)</td><td align="center" rowspan="1" colspan="1">0.07<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>(*)</label><p>Fisher exact test (two-tailed);</p></fn><fn id="TFN2"><label>(&#x02020;)</label><p>Mann-Whitney test (two-tailed); CVP: central venous pressure; CV:
coefficient of variation.</p></fn></table-wrap-foot></table-wrap><p>The analysis of comorbidities evidenced no statistical difference between the groups
(<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Assessed comorbidities according to group (G15: CVP control &#x02264; 15
cmH<sub>2</sub>O; and G20: CVP control &#x02264; 20 cmH<sub>2</sub>O)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">G15 (n = 70)</th><th align="center" rowspan="1" colspan="1">G20 (n = 70)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">18 (25.71)</td><td align="center" rowspan="1" colspan="1">25 (35.71)</td><td align="center" rowspan="1" colspan="1">0.07<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">10 (14.28)</td><td align="center" rowspan="1" colspan="1">11 (15.71)</td><td align="center" rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral arterial disease, n (%)</td><td align="center" rowspan="1" colspan="1">7 (10.00)</td><td align="center" rowspan="1" colspan="1">12 (17.14)</td><td align="center" rowspan="1" colspan="1">0.27<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Previous recent AMI, n (%)</td><td align="center" rowspan="1" colspan="1">28 (40)</td><td align="center" rowspan="1" colspan="1">23 (32.85)</td><td align="center" rowspan="1" colspan="1">0.48<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">LVD (EF &#x0003c; 50%), n (%)</td><td align="center" rowspan="1" colspan="1">8 (11.42)</td><td align="center" rowspan="1" colspan="1">16 (22.85)</td><td align="center" rowspan="1" colspan="1">0.11<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Renal function (GFR), mL/min (CV)</td><td align="center" rowspan="1" colspan="1">85.78 (0.37)</td><td align="center" rowspan="1" colspan="1">88.32 (0.49)</td><td align="center" rowspan="1" colspan="1">0.48 <sup><xref ref-type="table-fn" rid="TFN4">&#x02020;</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>(*)</label><p>Fisher exact test (two-tailed);</p></fn><fn id="TFN4"><label>(&#x02020;)</label><p>Mann-Whitney test (two-tailed); CVP: central venous pressure; COPD:
chronic obstructive pulmonary disease; AMI: acute myocardial infarction;
LVD: left ventricular dysfunction; EF: ejection fraction; CV:
coefficient of variation; GFR: glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><p>In the 48-72 post-CABG hours, the incidence of AF differed statistically between the
groups (<xref ref-type="table" rid="t3">Table 3</xref>). In G15, 8.56% of the
patients developed AF, in contrast to 22.86% of those in G20 (p = 0.03). The ARR was
14.28% [95% confidence interval (95% CI): 2.14-26.28], and RRR were used of 62.50%
(95% CI: 9.79-84.41) and NNT of 7. The sample power was 64.40%.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of atrial fibrillation within 72 postoperative hours, in-hospital
death, hospital length of stay after coronary artery bypass grafting, number
of grafts and use of cardiopulmonary bypass between patients with CVP
control &#x02264; 15 cmH<sub>2</sub>O (G15) and CVP control &#x02264; 20
cmH<sub>2</sub>O (G20)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">G15 (n = 70)</th><th align="center" rowspan="1" colspan="1">G20 (n = 70)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation, n (%)</td><td align="center" rowspan="1" colspan="1">6 (8.57)</td><td align="center" rowspan="1" colspan="1">16 (22.86)</td><td align="center" rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="TFN5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">In-hospital death, n (%)</td><td align="center" rowspan="1" colspan="1">4 (5.71)</td><td align="center" rowspan="1" colspan="1">8 (11.42)</td><td align="center" rowspan="1" colspan="1">0.07<xref ref-type="table-fn" rid="TFN5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital length of stay, mean, days (CV)</td><td align="center" rowspan="1" colspan="1">7.14 (0.70)</td><td align="center" rowspan="1" colspan="1">8.21 (0.68)</td><td align="center" rowspan="1" colspan="1">0.36<sup><xref ref-type="table-fn" rid="TFN6">&#x02020;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Grafts, median</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.22 <sup><xref ref-type="table-fn" rid="TFN6">&#x02020;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass, n (%)</td><td align="center" rowspan="1" colspan="1">47 (67.10)</td><td align="center" rowspan="1" colspan="1">39 (55.70)</td><td align="center" rowspan="1" colspan="1">0.22<xref ref-type="table-fn" rid="TFN5">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>(*)</label><p>Fisher exact test (two-tailed);</p></fn><fn id="TFN6"><label>(&#x02020;)</label><p>Mann-Whitney test (two-tailed); CVP: central venous pressure; CV:
coefficient of variation.</p></fn></table-wrap-foot></table-wrap><p>In G15, there were 4 in-hospital deaths, 2 due to pulmonary sepsis and 2 due to
stroke. In G20, there were 8 in-hospital deaths, 5 due to stroke, 2 due to pulmonary
sepsis and 1 due to urinary sepsis. Mortality showed no statistical difference (p =
0.07). In addition, there was no difference regarding the post-CABG hospital length
of stay (days), number of grafts, and use of CPB.</p><p>In the group of patients who developed AF, the following variables were analyzed:
mortality, hospital length of stay, number of grafts, and use of CPB (<xref ref-type="table" rid="t4">Table 4</xref>). Age differed statistically between
the groups (p = 0.04), with mean of 65.68 years among patients who developed AF, and
of 60.73 among those who did not develop AF. The hospital length of stay was
significant (p = 0.0012) among patients who developed AF, with mean of 10.22 days
(CV = 0.70). The other variables were statistically similar.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of age, mortality, hospital length of stay, number of grafts and
use of cardiopulmonary bypass between patients who developed atrial
fibrillation (AF) and those who did not</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">With AF (n = 22; 15.17%)</th><th align="center" rowspan="1" colspan="1">Without AF (n = 118; 84.29%)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (CV)</td><td align="center" rowspan="1" colspan="1">65.68 (0.15)</td><td align="center" rowspan="1" colspan="1">60.73 (0.16)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">In-hospital death, n (%)</td><td align="center" rowspan="1" colspan="1">2 (5.71%)</td><td align="center" rowspan="1" colspan="1">10 (11.42%)</td><td align="center" rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital length of stay, mean, days (CV)</td><td align="center" rowspan="1" colspan="1">10.22 (0.70)</td><td align="center" rowspan="1" colspan="1">7.20 (0.67)</td><td align="center" rowspan="1" colspan="1">0.001<sup><xref ref-type="table-fn" rid="TFN8">&#x02020;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Grafts, median</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.69<sup><xref ref-type="table-fn" rid="TFN8">&#x02020;</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass, n (%)</td><td align="center" rowspan="1" colspan="1">12 (54.55)</td><td align="center" rowspan="1" colspan="1">74 (62.71)</td><td align="center" rowspan="1" colspan="1">0.48<xref ref-type="table-fn" rid="TFN7">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>(*)</label><p>Fisher exact test (two-tailed);</p></fn><fn id="TFN8"><label>(&#x02020;)</label><p>Mann-Whitney test (two-tailed); CV: coefficient of variation.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>This study compared the AF incidence in the first 72 post-CABG hours using two CVP
control strategies, based on intention to treat, that is, the use of a diuretic was
aimed at maintaining CVP below the cutoff points. Patients maintained with CVP
&#x02264; 15 cmH<sub>2</sub>O in that period had lower AF incidence as compared to
patients whose CVP was maintained &#x02264; 20 cmH<sub>2</sub>O (8.56% vs. 22.86%; p
= 0.03). Measures of effect size were relevant: ARR of group G15 was 12.12%,
equivalent to a NNT of 7, that is, 1 in every 7 patients benefited from CVP control
&#x02264; 15 cmH<sub>2</sub>O after CABG, suggesting that maintaining CVP under
control can be effective in reducing AF incidence. The AF incidences in each group
and in the whole sample (15.71%) are similar to those reported in the literature
(5-40%).<sup><xref rid="r4" ref-type="bibr">4</xref></sup> The CVP was
measured with a monitor in mm Hg and in water column; we chose to use the water
column measure because some patients had only 24 hours of mmHg monitoring. For
patients stable after 24 hours, it is routine procedure to end invasive blood
pressure monitoring, CVP being controlled only by use of water column.</p><p>Atrial fibrillation in the PO period increases the risk for ischemic stroke,
ventricular tachycardia, ventricular fibrillation, hypotension and heart
failure.<sup><xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r7" ref-type="bibr">7</xref></sup> Post-CABG AF is associated with increased hospital
length of stay after surgery and in-hospital mortality.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> Sobral et al.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> have reported a longer hospital length of stay of patients
with AF (mean of 16.4 days; p = 0.004); however, they have not established whether
AF was the cause of prolonged hospitalization or an indicator of the severity of
more critically-ill patients. In addition, they have reported a peak incidence of
2.6 days (median, 2 days). Da Silva et al.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> have shown a mean hospital length of stay of patients who
developed AF after cardiac surgery of 16.9 days (p = 0.001). In their sample, the
hospital length of stay was significantly longer among patients with AF (p =
0.0012). They have not assessed the peak incidence in relation to that time, but the
period studied (72 hours) is in accordance with the predicted time in the literature
for higher AF incidence.<sup><xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> The mortality rate reported by Sobral et al.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> 1 year after surgery was 4.7% (n =
109; p = 0.001) for patients who developed AF, with a 30-day rehospitalization rate
of 7.6% (n = 168; p = 0.004) and an 1-year rehospitalization rate of 18.7% (n = 417;
p = 0.004). In our sample, in-hospital mortality and hospital length of stay were
assessed, and were slightly higher in G20, but with no statistical difference.</p><p>Knowing the risk factors for post-CABG AF is highly important. It enables the use of
prophylactic measures, aimed at reducing the incidence of AF, as well as of its
complications.<sup><xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup></p><p>Some risk factors for AF have been demonstrated. Age over 65 years<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> has been reported as one of the most important risk
factors.<sup><xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r12" ref-type="bibr">12</xref></sup> Age is associated with myocardial structural
changes due to degenerative processes (fibrosis and dilatation), which lead to lack
of an effective refractory period, dispersion of atrial refractoriness and abnormal
conduction and automaticity.<sup><xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r7" ref-type="bibr">7</xref></sup> In addition, advanced age is related
to increased in-hospital mortality.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> In our study, mean age was 60 years in G15, and 63 years in G20,
with no statistical difference (p = 0.07). Age showed significance when analyzing
patients who developed AF as compared to those who did not (p = 0.04). The mean age
of those who developed AF was 66 years, similarly to that reported in the
literature.<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p><p>Diabetes mellitus leads to metabolic changes, such as increased oxidative stress,
elevated levels of free fatty acids, and chronic tissue inflammation. Such
alterations result in changes in atrial structure and electrical conduction,
contributing to AF development in the PO period.<sup><xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r13" ref-type="bibr">13</xref></sup> In our sample, the
prevalence of diabetes mellitus was similar in both groups (p = 0.07).</p><p>Peripheral arterial occlusive disease associates with the severity of the patients'
clinical profile and comorbidities that predispose to the appearance of AF after
cardiac surgery.<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup> El-Chami et al.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> have identified peripheral arterial disease as a
risk factor for AF, and considered it an independent predictor of mortality. In our
study, the peripheral arterial occlusive disease prevalence did not statistically
differ between the groups.</p><p>Other conditions associated with the development of post-CABG AF are COPD,<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup> chronic renal
failure,<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup> previous AMI,<sup><xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup> and left
ventricular dysfunction.<sup><xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref></sup> The prevalence of those risk
factors was similar in both groups.</p><p>The number of grafts performed during CABG and the use of CPB have been identified as
risk factors,<sup><xref rid="r7" ref-type="bibr">7</xref></sup> but with some
disagreement between different authors.<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r14" ref-type="bibr">14</xref>-<xref rid="r19" ref-type="bibr">19</xref></sup> The CPB
is an invasive technique related to atrial ischemia and inflammatory response in the
PO period of cardiac surgeries.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r20" ref-type="bibr">20</xref></sup> The groups studied showed no
statistical difference regarding those parameters.</p><p>Some strategies for post-CABG AF prevention have been developed, especially those
related to pharmacological prophylaxis. Beta-blockers are the drugs of choice,
because they significantly reduce the AF incidence, being related to lower PO
morbidity and mortality.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r21" ref-type="bibr">21</xref></sup> They belong to the
most studied and used drug class, especially because of the control they have on the
increased sympathetic tone in patients submitted to cardiac surgery.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r6" ref-type="bibr">6</xref></sup> Beta-blockers are indicated for all patients undergoing CABG,
except in the presence of contraindications.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r21" ref-type="bibr">21</xref></sup> Prophylaxis with amiodarone and intravenous
magnesium is recommended when beta-blockers are contraindicated.<sup><xref rid="r22" ref-type="bibr">22</xref></sup> In older studies, the use of
statins in the preoperative and PO periods was considered relevant to post-CABG AF
prevention. Those drugs act by reducing the inflammation of patients with coronary
arterial disease. A meta-analysis by Zheng et al.<sup><xref rid="r23" ref-type="bibr">23</xref></sup> has shown that statin therapy significantly
reduced the AF incidence and hospital length of stay. Bockeria et al.<sup><xref rid="r24" ref-type="bibr">24</xref></sup> have shown that patients receiving
statin before CABG had higher benefits in preventing early AF than those who did
not. However, the literature is still controversial. In a recent
meta-analysis,<sup><xref rid="r25" ref-type="bibr">25</xref></sup> the
authors have concluded that PO statin therapy does not prevent AF in patients
undergoing elective cardiac surgery. At our service, the use of beta-blockers and
statins is maintained in the preoperative period and reintroduced with diet usually
on the first PO day. If the patient is on dobutamine or noradrenaline, the
beta-blocker is introduced after suspension of the vasoactive drug.</p><p>CVP is an important predictor of early mortality, independently of cardiac output and
other variable clinical conditions, mainly in the first 6 PO hours, because of
hemodynamic instability.<sup><xref rid="r26" ref-type="bibr">26</xref></sup> Strict
CVP control is aimed at measuring the pressure to which the atria are submitted,
taking the intravascular volume into consideration. The result of the intravascular
volume overload is hypertension, atrial dilatation and contraction reduction,
because of stretching of cardiac muscle fibers. However, that can be reversed with
diuretics.<sup><xref rid="r26" ref-type="bibr">26</xref>-<xref rid="r28" ref-type="bibr">28</xref></sup> Kalus et al.<sup><xref rid="r29" ref-type="bibr">29</xref></sup> have shown that hemodynamic
control based on the administration of large amounts of fluids accounted for the
increase in atrial pressure, and could trigger AF in the PO period of cardiothoracic
surgery. They have observed that cardiothoracic surgery patients who developed AF
had received approximately 1 liter of fluids more than those who did not develop
that arrhythmia, and that difference was more significant on the second PO day (p =
0.04). The limiting factor of that study was the lack of documentation of the
increase in atrial pressure and volume after surgery.</p><p>Intravascular volume overload causes abnormal dispersion of atrial refractory period,
because of the increase in atrial volume and pressure. Thus, the atrium becomes
vulnerable to the development of AF.<sup><xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref></sup> Hwang et
al.<sup><xref rid="r31" ref-type="bibr">31</xref></sup> have suggested that
intravascular volume is an important parameter, as are arterial gas analysis,
hemoglobin and serum potassium, which should be assessed when there is post-CABG AF,
because they can clarify the reversible causes of that arrhythmia. In addition,
Silva et al.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> have shown that
excessive fluid balance in the first 24 PO hours is a risk factor for post-CABG AF.
Those authors have reported pulmonary congestion as a trigger for that arrhythmia.
Koletsis et al.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> have reported an
association between positive fluid balance, reflecting an excessive intravascular
volume, and occurrence of post-CABG AF. In addition, the positive fluid balance has
been accounted for the increase in left atrial pressure and pulmonary congestion,
leading to hypoxia.</p><p>The increased left atrial volume identified in the preoperative period predisposes to
the development of AF after cardiac surgery. Wang et al.<sup><xref rid="r32" ref-type="bibr">32</xref></sup> have shown that the left atrial expansion index
was associated with in-hospital mortality and post-CABG AF, being an independent
risk factor. Osranek et al.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> have
reported that an increase over 32 mL/m<sup>2</sup> in left ventricular volume
increases by 5 times the risk for AF, as a factor independent of age and other
surgical parameters. Patel et al.<sup><xref rid="r33" ref-type="bibr">33</xref></sup> have found that for every 5-mm increase in the left atrium, on
the echocardiogram, the risk for AF increases by 39%. Sanfilippo et al.<sup><xref rid="r30" ref-type="bibr">30</xref></sup> have concluded that maintaining
sinus rhythm prevents the progression of left atrial hypertrophy and its adverse
effects. Maceira et al.<sup><xref rid="r34" ref-type="bibr">34</xref></sup> have
studied the right atrial dimensions by use of magnetic resonance imaging. The best
independent indicators of increased atrial volume were area greater than 16
cm<sup>2</sup>/m<sup>2</sup> and longitudinal diameter greater than 3.5
cm/m<sup>2</sup>. The present study did not assess left atrial volume in the
preoperative period, because not all patients underwent echocardiography before
surgery.</p><p>In our study, CVP maintained &#x02264; 15 cmH<sub>2</sub>O proved to be important to
prevent post-CABG AF, as compared to CVP &#x02264; 20 cmH<sub>2</sub>O. The
statistical power of the sample was satisfactory (66.70%); however, further studies,
with larger samples, are required to validate that approach as a prophylactic
measure against AF in the PO period of cardiac surgery. Our data suggest that
stricter CVP control is advantageous to prevent excessive volume overloads. Neither
mortality after discharge, nor the appearance of AF after that have been assessed.
Another study<sup><xref rid="r35" ref-type="bibr">35</xref></sup> has shown that
strict CVP control can prevent post-CABG AF as compared to no CVP control. Our study
strategy proved beneficial (NNT = 7) in this relatively small sample (140 patients)
in a single-center study.</p><p>Multicenter studies with a larger sample that can assess not only AF incidence, but
also mortality and the increase in costs with longer hospital length of stay, are
required to better assess this type of treatment. It is worth noting that the use of
diuretics caused no harm to the patients, there was increase in neither renal
failure nor hemodynamic instability, in addition to being a very low cost strategy.
Thus, CVP control can serve as a complementary method in post-CABG AF
prophylaxis.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The CVP control maintained &#x02264; 15 cmH<sub>2</sub>O, in the first 48-72 PO hours,
can reduce the incidence of post-CABG AF. One in every seven patients benefits from
that strategy.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research: Costa MAC, Lirani W, Wippich AC,
Schafranski MD; Acquisition of data, Analysis and interpretation of the data,
Statistical analysis, Writing of the manuscript and Critical revision of the
manuscript for intellectual contente: Costa MAC, Lirani W, Wippich AC, Lopes L,
Tolentino ES, Zampar B, Schafranski MD; Obtaining financing: Costa MAC, Lirani
W, Schafranski MD.</p></fn><fn fn-type="COI-statement"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This study is not associated with any thesis or dissertation work.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>LP</given-names></name><name><surname>Figueiredo</surname><given-names>MJO</given-names></name><name><surname>Cintra</surname><given-names>FD</given-names></name><name><surname>Saas</surname><given-names>EB</given-names></name><name><surname>Keniyishi</surname><given-names>RR</given-names></name><name><surname>Teixeira</surname><given-names>RA</given-names></name><etal/><collab>Sociedade Brasleira de Cardiologia</collab></person-group><article-title>II Diretrizes Brasileiras de Fibrila&#x000e7;&#x000e3;o
Atrial</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>106</volume><issue>4</issue><supplement>supl.2</supplement><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>January</surname><given-names>CT</given-names></name><name><surname>Wann</surname><given-names>LS</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Cleveland</surname><given-names>JC</given-names></name><name><surname>Cigarroa</surname><given-names>JE</given-names></name><etal/></person-group><article-title>2014 AHA/ACC/HRS Guideline for the Management of Patients With
Atrial Fibrillation: A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the Heart Rhythm
Society</article-title><source>Circulation</source><year>2014</year><volume>130</volume><issue>23</issue><fpage>199</fpage><lpage>267</lpage></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>HV</given-names></name><name><surname>Fischer</surname><given-names>GW</given-names></name></person-group><article-title>Atrial fibrillation: pathophysiology and therapeutic
options</article-title><source>J Cardiothorac Vasc Anesth</source><year>2015</year><volume>29</volume><issue>5</issue><fpage>1333</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">26384632</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>A</given-names></name><name><surname>EL-Haddad</surname><given-names>MA</given-names></name><name><surname>Shenoy</surname><given-names>M</given-names></name><name><surname>Tuliani</surname><given-names>T</given-names></name></person-group><article-title>Atrial fibrillation post cardiac bypass surgery</article-title><source>Avicenna J Med</source><year>2012</year><volume>2</volume><issue>3</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">23826549</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echahidi</surname><given-names>N</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>O'Hara</surname><given-names>G</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms, prevention, and treatment of atrial fibrillation
after cardiac surgery</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><issue>8</issue><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">18294562</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomivorotov</surname><given-names>VV</given-names></name><name><surname>Efremov</surname><given-names>SM</given-names></name><name><surname>Pokushalov</surname><given-names>EA</given-names></name><name><surname>Karaskov</surname><given-names>AM</given-names></name></person-group><article-title>New-onset atrial fibrillation after cardiac surgery:
pathophysiology, prophylaxis, and treatment</article-title><source>J Cardiothorac Vasc Anesth</source><year>2016</year><volume>30</volume><issue>1</issue><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">26597469</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferro</surname><given-names>CR</given-names></name><name><surname>Oliveira</surname><given-names>DC</given-names></name><name><surname>Nunes</surname><given-names>FP</given-names></name><name><surname>Piegas</surname><given-names>LS</given-names></name></person-group><article-title>Fibrila&#x000e7;&#x000e3;o atrial no p&#x000f3;s-operat&#x000f3;rio
de cirurgia card&#x000ed;aca</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>1</issue><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19838472</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelazzi</surname><given-names>C</given-names></name><name><surname>Villa</surname><given-names>G</given-names></name><name><surname>De Gaudio</surname><given-names>AR</given-names></name></person-group><article-title>Postoperative atrial fibrillation</article-title><source>ISRN Cardiol</source><year>2011</year><fpage>203179</fpage><lpage>203179</lpage><pub-id pub-id-type="pmid">22347631</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobral</surname><given-names>MLP</given-names></name><name><surname>Barbieri</surname><given-names>LR</given-names></name><name><surname>Ger&#x000f4;nimo</surname><given-names>GMS</given-names></name><name><surname>Trompieri</surname><given-names>DF</given-names></name><name><surname>Souza</surname><given-names>TA</given-names></name><name><surname>Rocca</surname><given-names>JMG</given-names></name><etal/></person-group><article-title>Impacto postoperative atrial fibrillation after coronary artery
by-pass grafting in ICU stay and readmission rates</article-title><source>RELAMPA Rev Lat.-Am. Marcapasso Arritm</source><year>2013</year><volume>26</volume><issue>3</issue><fpage>137</fpage><lpage>143</lpage></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>RG</given-names></name><name><surname>Lima</surname><given-names>GG</given-names></name><name><surname>Laranjeira</surname><given-names>ACAR</given-names></name><name><surname>Pereira</surname><given-names>E</given-names></name><name><surname>Rodrigues</surname><given-names>R</given-names></name></person-group><article-title>Risk factors, morbidity, and mortality associated with atrial
fibrillation in the postoperative period of cardiac surgery</article-title><source>Arq Bras Cardiol;</source><year>2004</year><volume>83</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raiten</surname><given-names>JM</given-names></name><name><surname>Ghadimi</surname><given-names>K</given-names></name><name><surname>Augoustides</surname><given-names>JG</given-names></name><name><surname>Ramakrishna</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>PA</given-names></name><name><surname>Weiss</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Atrial fibrillation after cardiac surgery: clinical update on
mechanisms and prophylactic strategies</article-title><source>J Cardiothorac Vasc Anesth</source><volume>29</volume><issue>3</issue><fpage>806</fpage><lpage>816</lpage></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>DC</given-names></name><name><surname>Ferro</surname><given-names>CR</given-names></name><name><surname>Oliveira</surname><given-names>JB</given-names></name><name><surname>Prates</surname><given-names>GJ</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Egito</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Post-operative atrial fibrillation following coronary artery
by-pass graft: clinical factors associated with in-hospital
death</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>89</volume><issue>1</issue><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">17768578</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thor&#x000e9;n</surname><given-names>E</given-names></name><name><surname>Hellgren</surname><given-names>L</given-names></name><name><surname>St&#x000e5;hle</surname><given-names>E</given-names></name></person-group><article-title>High incidence of atrial fibrillation after coronary
surgery</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2016</year><volume>22</volume><issue>2</issue><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">26598007</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Chami</surname><given-names>MF</given-names></name><name><surname>Kilgo</surname><given-names>PD</given-names></name><name><surname>Elfstrom</surname><given-names>KM</given-names></name><name><surname>Halkos</surname><given-names>M</given-names></name><name><surname>Thourani</surname><given-names>V</given-names></name><name><surname>Lattouf</surname><given-names>OM</given-names></name><etal/></person-group><article-title>Prediction of new onset atrial fibrillation after cardiac
revascularization surgery</article-title><source>Am J Cardiol</source><year>2012</year><volume>110</volume><issue>5</issue><fpage>649</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">22621801</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koletsis</surname><given-names>EN</given-names></name><name><surname>Prokakis</surname><given-names>C</given-names></name><name><surname>Crockett</surname><given-names>JR</given-names></name><name><surname>Dedeilias</surname><given-names>P</given-names></name><name><surname>Panagiotou</surname><given-names>M</given-names></name><name><surname>Panagopoulos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prognostic factors of atrial fibrillation following elective
coronary artery bypass grafting: the impact of quantified intraoperative
myocardial ischemia</article-title><source>J Cardiothorac Surg</source><year>2011</year><volume>6</volume><fpage>127</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">21967892</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osranek</surname><given-names>M</given-names></name><name><surname>Fatema</surname><given-names>K</given-names></name><name><surname>Qaddoura</surname><given-names>F</given-names></name><name><surname>Al-Saileek</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>ME</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><etal/><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Tsang</surname><given-names>TS</given-names></name><name><surname>Zehr</surname><given-names>KJ</given-names></name><name><surname>Seward</surname><given-names>JB</given-names></name></person-group><article-title>Left atrial volume predicts the risk of atrial fibrillation after
cardiac surgery: a prospective study</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><issue>4</issue><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">16904549</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Hyun</surname><given-names>DW</given-names></name><name><surname>Jung</surname><given-names>BC</given-names></name><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Shin</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Left atrial volume index as a predictor for occurrence of atrial
fibrillation after ablation of typical atrial flutter</article-title><source>J Cardiol</source><year>2010</year><volume>56</volume><issue>3</issue><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">20889311</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotfi</surname><given-names>A</given-names></name><name><surname>Wartak</surname><given-names>S</given-names></name><name><surname>Sethi</surname><given-names>P</given-names></name><name><surname>Garb</surname><given-names>J</given-names></name><name><surname>Giugliano</surname><given-names>GR</given-names></name></person-group><article-title>Postoperative atrial fibrillation is not associated with an
increased risk of stroke or the type and number of grafts: a single-center
retrospective analysis</article-title><source>Clin Cardiol</source><year>2011</year><volume>34</volume><issue>12</issue><fpage>787</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">22120735</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariscalco</surname><given-names>G</given-names></name><name><surname>Musumeci</surname><given-names>F</given-names></name><name><surname>Banach</surname><given-names>M</given-names></name></person-group><article-title>Factors influencing post-coronary artery bypass grafting atrial
fibrillation episodes</article-title><source>Kardiol Pol</source><year>2013</year><volume>71</volume><issue>11</issue><fpage>1115</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">24297708</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadic</surname><given-names>M</given-names></name><name><surname>Ivanovic</surname><given-names>B</given-names></name><name><surname>Zivkovic</surname><given-names>N</given-names></name></person-group><article-title>Predictors of atrial fibrillation following coronary artery
bypass surgery</article-title><source>Med Sci Monit</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>CR48</fpage><lpage>CR55</lpage><pub-id pub-id-type="pmid">21169910</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koniari</surname><given-names>I</given-names></name><name><surname>Apostolakis</surname><given-names>E</given-names></name><name><surname>Rogkakou</surname><given-names>C</given-names></name><name><surname>Baikoussis</surname><given-names>NG</given-names></name><name><surname>Dougenis</surname><given-names>D</given-names></name></person-group><article-title>Pharmacologic prophylaxis for atrial fibrillation following
cardiac surgery: a systematic review</article-title><source>J Cardiothorac Surg</source><year>2010</year><volume>5</volume><fpage>121</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">21118555</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frendl</surname><given-names>G</given-names></name><name><surname>Sodickson</surname><given-names>AC</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Waldo</surname><given-names>AL</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Tesdale</surname><given-names>JE</given-names></name><etal/></person-group><article-title>2014 AATS Guidelines for the prevention and management of
peri-operative atrial fibrillation and flutter (POAF) for thoracic surgical
procedures</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>153</fpage><lpage>193</lpage></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>ZL</given-names></name><name><surname>Shan</surname><given-names>JG</given-names></name><name><surname>Yang</surname><given-names>WG</given-names></name></person-group><article-title>The use of statins to prevent postoperative atrial fibrillation
after coronary artery bypass grafting: a meta-analysis of 12
studies</article-title><source>J Cardiovasc Pharmacol</source><year>2014</year><volume>64</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">24705176</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockeria</surname><given-names>OL</given-names></name><name><surname>Akhobekov</surname><given-names>AA</given-names></name><name><surname>Shvartz</surname><given-names>VA</given-names></name><name><surname>Kudzoeva</surname><given-names>ZF</given-names></name></person-group><article-title>Efficacy of Statin Therapy in the Prevention of Atrial
Fibrillation in Early Postoperative Period after Coronary Artery Bypass
Grafting</article-title><source>Vestn Ross Akad Med Nauk</source><year>2015</year><issue>3</issue><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">26495714</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Jayaram</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Perioperative rosuvastatin in cardiac surgery</article-title><source>N Engl J Med</source><year>2016</year><issue>374</issue><fpage>1744</fpage><lpage>1753</lpage><pub-id pub-id-type="pmid">27144849</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Wojdyla</surname><given-names>D</given-names></name><name><surname>Harskamp</surname><given-names>R</given-names></name><name><surname>Southerland</surname><given-names>KW</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Central venous pressure after coronary artery bypass surgery:
does it predict postoperative mortality or renal failure?</article-title><source>J Crit Care</source><year>2014</year><volume>29</volume><issue>6</issue><fpage>1006</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">25035048</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrigo</surname><given-names>M</given-names></name><name><surname>Bettex</surname><given-names>D</given-names></name><name><surname>Rudiger</surname><given-names>A</given-names></name></person-group><article-title>Management of atrial fibrillation in critically Ill
patients</article-title><source>Crit Care Res Pract</source><year>2014</year><fpage>840615</fpage><lpage>840615</lpage><pub-id pub-id-type="pmid">24527212</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sibley</surname><given-names>S</given-names></name><name><surname>Muscedere</surname><given-names>J</given-names></name></person-group><article-title>New-onset atrial fibrillation in critically ill
patients</article-title><source>Can Respir J</source><year>2015</year><volume>22</volume><issue>3</issue><fpage>179</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">26057373</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalus</surname><given-names>JS</given-names></name><name><surname>Caron</surname><given-names>MF</given-names></name><name><surname>White</surname><given-names>CM</given-names></name><name><surname>Mather</surname><given-names>JF</given-names></name><name><surname>Gallagher</surname><given-names>R</given-names></name><name><surname>Boden</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Impact of fluid balance on incidence of atrial fibrillation after
cardiothoracic surgery</article-title><source>Am J Cardiol</source><year>2004</year><volume>94</volume><issue>11</issue><fpage>1423</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">15566917</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanfilippo</surname><given-names>AJ</given-names></name><name><surname>Abascal</surname><given-names>VM</given-names></name><name><surname>Sheehan</surname><given-names>M</given-names></name><name><surname>Oertel</surname><given-names>LB</given-names></name><name><surname>Harrigan</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Atrial enlargement as a consequence of atrial fibrillation: a
prospective echocardiographic study</article-title><source>Circulation</source><year>1990</year><volume>82</volume><issue>3</issue><fpage>792</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">2144217</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name></person-group><article-title>Early restoration of atrial contractility after new-onset atrial
fibrillation in off-pump coronary revascularization</article-title><source>Ann Thorac Surg</source><year>2013</year><volume>95</volume><issue>2</issue><fpage>520</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">23201104</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Hsiao</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>KL</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Kang</surname><given-names>PL</given-names></name><name><surname>Chiou</surname><given-names>KR</given-names></name></person-group><article-title>Left atrial expansion index for predicting atrial fibrillation
and in-hospital mortality after coronary artery bypass graft
surgery</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>93</volume><issue>3</issue><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">22226234</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>DA</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Gilliland</surname><given-names>Y</given-names></name></person-group><article-title>Clinical implications of left atrial enlargement: a
review</article-title><source>Ochsner J</source><year>2009</year><volume>9</volume><issue>4</issue><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">21603443</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maceira</surname><given-names>AM</given-names></name><name><surname>Cos&#x000ed;n-Sales</surname><given-names>J</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Prasad</surname><given-names>SK</given-names></name><name><surname>Pennell</surname><given-names>DJ</given-names></name></person-group><article-title>Reference right atrial dimensions and volume estimation by steady
state free precession cardiovascular magnetic resonance</article-title><source>J Cardiovasc Magn Reson</source><year>2013</year><volume>15</volume><issue>1</issue><fpage>29</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">23566426</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>MAC</given-names></name><name><surname>Wippich</surname><given-names>AC</given-names></name><name><surname>Schafranski</surname><given-names>MD</given-names></name><name><surname>Zampar</surname><given-names>B</given-names></name><name><surname>Tolentino</surname><given-names>ES</given-names></name><name><surname>Lirani</surname><given-names>W</given-names></name></person-group><article-title>Efeito do controle da press&#x000e3;o venosa central na
ocorr&#x000ea;ncia de fibrila&#x000e7;&#x000e3;o atrial ap&#x000f3;s
revasculariza&#x000e7;&#x000e3;o do mioc&#x000e1;rdio: estudo
caso-controle</article-title><source>RELAMPA Rev. Lat.-Am. Marcapasso Arritm</source><year>2014</year><volume>27</volume><issue>3</issue><fpage>129</fpage><lpage>135</lpage></element-citation></ref></ref-list></back></article>